Stock News

Cathie Wood Doubles Down on These 2 Innovation Stocks

0

S&P 500

3,673.90

+90.83(+2.53%)

 

Dow 30

30,190.35

+555.52(+1.87%)

 

Nasdaq

10,640.16

+318.77(+3.09%)

 

Russell 2000

1,729.05

+46.65(+2.77%)

 

Crude Oil

86.83

+1.22(+1.43%)

 

Gold

1,671.80

+22.90(+1.39%)

 

Silver

18.83

+0.75(+4.17%)

 

EUR/USD

0.9790

+0.0066(+0.68%)

 

10-Yr Bond

3.9240

-0.0860(-2.14%)

 

GBP/USD

1.1337

+0.0157(+1.40%)

 

USD/JPY

148.7880

+0.0680(+0.05%)

 

BTC-USD

19,622.87

+481.27(+2.51%)

 

CMC Crypto 200

445.98

+10.51(+2.41%)

 

FTSE 100

6,949.04

+90.25(+1.32%)

 

Nikkei 225

26,775.79

-314.97(-1.16%)

 

Not many hedge managers have ignited as much controversy as Cathie Wood. The founder of Ark Invest has built her brand on running against the crowd. From her early embrace of tech stocks to her outspoken political conservatism, Cathie Wood has always been something of a lightning rod.

Wood is staking her reputation and fortune on a belief that new technologies, and especially the way that new technologies will interact with each other, are going to completely transform our world. In her view, sectors such as artificial intelligence, blockchain, genomic, and robotics can provide new ways of seeing the world, and their combinations may bring us new medical treatments or autonomous mobility systems.

“We believe — and just to give some numbers — that truly disruptive innovation will scale from $7 trillion in market cap today to $210 trillion by 2030, from less than 10% of the broad base public equity market to more than 60. And so if you’re short innovation, you’re going to be missing some of these unbelievable opportunities,” Wood opined.

Now to be fair, we should note that Wood flagship fund, the ARK Innovation ETF, peaked in February of 2021, and that it is down 78% since then. But we should also note that this same ETF surged over 300% in the year after the COVID-based market crash of March 2020. As Yogi Berra famously said: ‘Its tough to make predictions, especially about the future.’ Time will tell if Wood is right – but her track record shows that she can’t be ignored.

So let’s take a closer look at two innovation stocks that Wood has been buying lately. According to the TipRanks platform, Wood is not the only one singing these stocks’ praises. Wall Street’s analysts have also voiced approval of them, and they both feature plenty of upside potential.

UiPath Inc. (PATH)

We’ll start with UiPath, a company specializing in robotic process automation, RPA, using a combination of artificial intelligence and machine learning to create automated software bots to take over the digital world’s boring and repetitive ordinary tasks. UiPath’s products promise digital customers benefits from cost savings, resilience, higher accuracy, improved regulatory compliance, and increased productivity. The company counts such major names as Google, Airbus, and GE among its customer base.

A look at the company’s last quarterly financial release, from Q2 of fiscal year 2023 – the quarter ending on July 31 – shows the underlying strength of UiPath’s offerings. The company had a top line of $242.2 million, up 24% in 12 months, and increased its annual recurring revenue, ARR, by 44% year-over-year to $1.043 billion. While the company posted a net earnings loss of 2 cents per share in the quarter, and a cash burn of more than $23 million, it also reported having $1.7 billion in cash and liquid assets on hand as of July 31.

At the same time, PATH shares have fallen 74% so far this year. So what we have here is an innovative company, working in AI and software automation, currently trading at a steep discount – and Cathie Wood took notice. She had already bought into this stock, but in the September-October period this year, her five ARK ETF funds bought up another 10.6 million shares of PATH. This gives her a total of 42,759,557 shares in PATH, a stake that is worth well over $475 million at current prices.

Wood is not the only bull on PATH. Wells Fargo analyst Michael Turrin has also taken an upbeat stance on this stock, writing of its prospects going forward: “Our main takeaway is that UiPath continues to make necessary changes to adapt to the current environment (+ prior period of hyper-growth) and maintain share within the burgeoning automation market. While the sharply decelerating profile is likely to keep PATH in the ‘show-me’ camp and shares volatile in the NT, suggestions automation remains a spend priority and the muted 2H/FY24 outlook present room for improvement well-beyond current expectations…”

To this end, Turrin rates PATH an Overweight (i.e. Buy), and sets a $16 price target to suggest an upside potential of ~44% over the course of the next 12 months. (To watch Turrin’s track record, click here)

Overall, PATH shares have a Moderate Buy rating from the analyst consensus. This is based on 17 recent reviews, which break down to 9 Buys and 8 Holds. The stock has a current trading price of $11.12 and its average price target of $18.38, more bullish than the Wells Fargo view, implies ~65% upside on the one-year horizon. (See PATH stock forecast on TipRanks)

Verve Therapeutics (VERV)

The second ‘Wood-pick’ we’ll look at is Verve Therapeutics, an early-clinical stage biopharma firm with a focus on cardiovascular disease. According to the World Health Organization, cardiovascular disease, which kills almost 18 million people globally every year, is the world’s leading cause of premature death. In the US, it is responsible for more than 610,000 deaths annually. Verve Therapeutics has taken aim at this collection of conditions, and is working on new medicines to bring new approaches to the treatment of coronary problems.

The company currently has two drug candidates in its pipeline. The first of these, VERVE-101, has recently entered the clinical trial stage, and patient dosing has begun in the heart-1 clinical trial in New Zealand. The drug candidate is a novel agent, a gene editing medicine designed to turn off the PCSK9 gene in the liver and reduce the production of the disease-driving low-density lipoprotein cholesterol (LDL-C). VERVE-101 has recently received clearance from the UK medicine and healthcare products regulatory agency for the clinical trial application in that country. The clearance is for heterozygous familial hypercholesterolemia, and the trial will be part of the recently begun heart-1 testing in New Zealand.

The second drug candidate, VERVE-201, is a proposed treatment for improving the body’s natural regulation of cholesterol and triglycerides through targeting of the ANGPT3 gene. This gene is involved in regulation of lipids, and offers a potential pathway for the treatment of hyperlipidemia. The company has recently released pre-clinical data at the European Society of Cardiology’s 2022 Congress, supporting the drug candidate’s nomination for clinical trials.

On the financial front, Verve is still pre-revenue, and in 2Q22 the company ran a net loss of $40.9 million, or 84 cents per share. Verve reported having $595 million in cash on hand, giving it a clear runway to conduct operations into 2H25.

In the meantime, Cathie Wood has been making large purchases of VERV shares. In September, she bought 831,145 shares through her ARK Innovation ETF, and another 321,630 shares through the ARK Genomic Revolution ETF. She now holds more than 859K shares through ARK Innovation, and about 2.37 million shares through ARK Genomic. Wood’s total VERV holding, of 3,229,636 shares between the two funds, is worth over $98 million.

Is it a good buy? Stifel analyst Dae Gon Ha believes so, basing his bullish stance on the potential upcoming catalysts in the pipeline.

“We think catalysts like VERVE-101 IND and its clinical data (2023) will drive shares. We plan on reassessing our long-term theses in due time but for now, our diligence on the upcoming catalysts (conversations with three ex-FDA KOLs and management, and IND clinical hold precedents) adds optimism to VERV’s 1-2 year outlook,” Ha noted.

“Even under a bear case of no IND for VERVE-101, NTLA-2001 precedent suggests that positive Ph.1 heart-1 data, irrespective of geography, may present meaningful upside from current levels. Admittedly, regulatory decisions are hard to handicap but given VERV’s extensive foundational work supporting VERVE-101, we think positive updates are more likely (than not),” the analyst added.

In line with his comments, Ha rates VERV shares a Buy, with a $56 target price that implies an 83% one-year upside potential. (To watch Ha’s track record, click here)

Overall, there are 9 recent analyst reviews of this stock on record and they break down 7 to 2 in favor of Buys over Holds, for a Strong Buy consensus rating. The shares are currently priced at $30.56 and the $53.13 average price target suggests a 12-year gain of ~74% lies ahead. (See VERV stock forecast on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Advertisement

Poets & Quants

Digging Deeper: More About Berkeley Haas’ Strong Jobs Report

Natasha Payes photo The UC-Berkeley Haas School of Business community had a lot to be pleased with in the school’s newly released 2022 employment report, starting with big jumps in both job offers and … The post Digging Deeper: More About Berkeley Haas’ Strong Jobs Report appeared first on Poets&Quants.

Reuters

Credit Suisse’s Meissner to leave bank after overhaul, source says

Credit Suisse investment bank chief Christian Meissner will be leaving the Swiss bank once it has announced a strategic overhaul, a person with knowledge of the matter said on Monday. Announcement of his departure is expected to be made along with the bank’s strategic review and quarterly earnings on Oct. 27, as first reported by Bloomberg News. A Credit Suisse spokesperson declined to comment when contacted by Reuters.

Motley Fool

3 Reasons to Buy Sea Limited Stock, and 3 Reasons to Sell

Sea Limited’s (NYSE: SE) stock plummeted nearly 80% this year and surrendered all of its gains from the past two and half a years. The Singapore-based e-commerce, fintech, and gaming giant lost its luster as its top line growth cooled off and its losses widened. Rising interest rates exacerbated the pain by broadly crushing higher-growth tech stocks.

Bloomberg

Egyptian Pound Has Bears Betting on 14% Drop as IMF Deal Nears

(Bloomberg) — Investors are bracing for steeper declines in the Egyptian pound, with the North African nation expected to seal a preliminary deal with the International Monetary Fund in just days.Most Read from BloombergRussia Hits Ukrainian Capital Kyiv With Kamikaze DronesNATO-China Tension Over Ukraine Flares at Conference in IcelandStocks Snap Back After Selloff With UK’s Reversal: Markets WrapThe Time to Buy the Dip Is Fast Approaching — for One CountryDerivatives traders stepped up bets t

The Wall Street Journal

Procter & Gamble Ups Marketing to Persuade Consumers on Pricier Products

Inflation is testing Americans’ loyalty to Procter & Gamble ’s biggest brands, but the maker of Tide detergent, Pampers diapers and Gillette razors is betting it can persuade shoppers to keep paying up. The world’s biggest maker of consumer products is rolling out star-studded ad campaigns and new product features, from drip-proof soap bottles to extra-absorbent paper towels, hoping to keep cash-crunched consumers from switching to cheaper brands. P&G in recent months has underperformed rivals both broadly and in key categories such as razors, laundry detergent and paper towels, according Nielsen data.

Insider Monkey

10 Stocks to Buy According to Teresa Barger’s Cartica Management

In this article, we discuss 10 stocks to buy according to Teresa Barger’s Cartica Management. If you want to skip our detailed analysis of Barger’s investment philosophy and performance, go directly to 5 Stocks to Buy According to Teresa Barger’s Cartica Management. In 2009, Teresa Barger cofounded Cartica Management, an alternative asset manager focused on […]

MarketWatch

Verizon has hit a speed bump, but earnings could show a better road ahead

After posting net losses of wireless retail postpaid phone subscribers in its consumer business during each of the past two quarters, Verizon (VZ) Chief Executive Hans Vestberg cautioned at a recent Goldman Sachs conference that the company expects a “churn bubble” for the third quarter as a result of price increases on certain plans. Verizon is facing some identity issues in the current wireless market. Verizon’s wireless deals have been seen as less aggressive than what some rivals were offering, though all of the major carriers were fairly promotional during the recent iPhone launch cycle.

Insider Monkey

11 Best Dividend Aristocrats With Over 3% Yield

In this article, we discuss 11 best dividend aristocrats with over 3% yield. You can skip our detailed analysis of the past performance of dividend aristocrats, and go directly to read 5 Best Dividend Aristocrats With Over 3% Yield. Dividend Aristocrats are the companies in the S&P 500 that have records of raising their dividends consistently […]

Bloomberg

Bank Run Shows Risks From Widening Vietnam Corruption Probes

(Bloomberg) — It was a jarring image for one of the world’s fastest growing economies: Scores of Vietnamese flooded branches of the nation’s fifth-largest bank to pull out their savings amid rumors the lender was tied to a real estate conglomerate under investigation for fraud.Most Read from BloombergRussia Hits Ukrainian Capital Kyiv With Kamikaze DronesNATO-China Tension Over Ukraine Flares at Conference in IcelandStocks Snap Back After Selloff With UK’s Reversal: Markets WrapThe Time to Buy

Motley Fool

Down 40% or More, These Beaten-Down Cash-Rich Companies Can Keep Growing Even If Things Get Worse

The stock market has taken a nasty fall this year. Investors are increasingly concerned that the Federal Reserve’s actions to combat red-hot inflation will put the economy in a tailspin. While their stock prices are down more than 40% from their peaks, making it much more expensive to raise equity capital, that won’t limit them since they generate a lot of cash and have cash-rich balance sheets.

Bloomberg

Small-Time Options Traders Bet Big on US Stocks Falling Further

(Bloomberg) — Look no further than retail traders for a picture of pessimistic sentiment toward US equities, with bets on declines outnumbering wagers on gains by more than three to one. Most Read from BloombergRussia Hits Ukrainian Capital Kyiv With Kamikaze DronesNATO-China Tension Over Ukraine Flares at Conference in IcelandStocks Snap Back After Selloff With UK’s Reversal: Markets WrapThe Time to Buy the Dip Is Fast Approaching — for One CountrySmall-lot options traders — those buying no m

MarketWatch

Roblox stock surges after growth in September DAUs and bookings, while previous revenue estimates adjusted down

Roblox Corp. reported September metrics Monday that showed average daily active users (DAUs) rose 23% from a year ago to 57.8 million, which was down from 59.9 million in August but up from 52.2 million in July. Hours engaged for the month were up 16% to 4.0 billion, while estimated bookings increased 11% to 15% to between $212 million and $219 million. The immersive digital experiences company’s stock surged 12.2% in premarket trading. The company also updated its “paying user life” estimate to

Motley Fool

Is AMD a Buy?

Advanced Micro Devices’ (NASDAQ: AMD) year went from bad to worse after the company released preliminary results for the third quarter of 2022 on Oct. 6. AMD investors pressed the panic button hard after the company revealed that its quarterly revenue would land at an estimated $5.6 billion at the midpoint of its updated guidance range. The company originally expected $6.7 billion in Q3 revenue, but a weak PC (personal computer) market has knocked the wind out of AMD’s sails.

Motley Fool

3 Red Flags for Carnival Stock

Down 67% year to date, Carnival Corporation (NYSE: CCL) has probably landed on some value investors’ radar. Like most cruise companies, Carnival was hurt by the COVID-19 pandemic, especially after the U.S. Centers for Disease Control’s (CDC) no-sail order scuttled its operations for much of 2020. As of the third quarter, Carnival reports $28.5 billion in long-term debt — up from just $9.7 billion at the end of 2019.

BTS stars to serve military duty in South Korea

Previous article

Stock market news live updates: Stocks rally ahead of big Q3 earnings week

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Stock News